Retatrutide is an investigational, once-weekly injectable medication that stands out by acting as a triple hormone receptor agonist, stimulating three critical pathways—GLP-1, GIP, and glucagon—to tackle hunger, improve metabolism, and regulate blood sugar more comprehensively than existing treatments such as semaglutide or tirzepatide. Early phase 2 results showed impressive outcomes: up to 17.5% average weight loss after 24 weeks, and up to 24% after 48 weeks in adults with obesity.
GLP‑1 receptor activation reduces appetite, slows gastric emptying, and enhances insulin secretion.
GIP receptor activation further boosts insulin release and supports fat metabolism.
Glucagon receptor activation promotes fat breakdown and increases energy expenditure.
This triple-action approach not only suppresses hunger, but also accelerates calorie burning—earning retatrutide its “turbocharged” reputation compared to dual-agonists like tirzepatide